Skip to main content
CMND
NASDAQ Life Sciences

Clearmind的CMND-100药物在一期/二期临床试验中达到一期末点，用于治疗酒精使用障碍

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$1.79
Mkt Cap
$2.987M
52W Low
$0.595
52W High
$52.4
Market data snapshot near publication time

summarizeSummary

Clearmind Medicine宣布，其用于酒精使用障碍（AUD）的CMND-100药物候选者在FDA批准的一期/二期临床试验中成功达到了一期末点。试验结果，包括第三队列的数据，表明CMND-100具有高安全性和良好的耐受性，即使在更高的剂量下也没有报告任何严重的不良事件。这一积极的结果是在同一试验中完成治疗和随访的各种队列的早期报告之后。对于一家临床阶段的生物技术公司来说，具有小市值，达到一期安全性和耐受性末点是一个关键的去风险事件，验证了该药物的基础安全性。这一重要的里程碑支持CMND-100作为一种潜在的新型、非致幻的治疗AUD的选择的持续开发。投资者现在将期待进一步更新该药物的开发途径，包括随后的临床试验计划和任何初步的疗效数据。

在该公告发布时，CMND的交易价格为$1.79，交易所为NASDAQ，所属行业为Life Sciences，市值约为$298.7万。 52周交易区间为$0.59至$52.40。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CMND - Latest Insights

CMND
Apr 27, 2026, 7:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Clearmind Medicine Evaluates Lead Candidate CMND-100 for FDA Breakthrough Therapy Designation
Sentiment: Positive
View Wiseek Article
CMND
Apr 27, 2026, 7:41 AM EDT
Source: GlobeNewswire
Importance Score:
7
Clearmind Medicine Eyes FDA Breakthrough Therapy Designation for CMND-100
Sentiment: Positive
View Wiseek Article
CMND
Apr 21, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
9
Clearmind Medicine Converts $2.68M in Notes into 4.47M Shares, Causing Significant Dilution
Sentiment: Negative
View Wiseek Article
CMND
Apr 20, 2026, 5:18 PM EDT
Filing Type: 6-K
Importance Score:
9
Clearmind Medicine Secures $2.43M in Highly Dilutive Convertible Note Financing
Sentiment: Negative
View Wiseek Article
CMND
Apr 20, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Presidential Executive Order Boosts Psychedelic Drug Development, Favors Clearmind's Pipeline
Sentiment: Positive
View Wiseek Article
CMND
Apr 15, 2026, 9:15 AM EDT
Filing Type: 6-K
Importance Score:
8
Clearmind Medicine's CMND-100 Trial Advances to Next Cohort with Increased Dose After Positive DSMB Review
Sentiment: Positive
View Wiseek Article
CMND
Apr 15, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
CMND-100 Trial Receives DSMB Approval to Advance, Increase Dose
Sentiment: Positive
View Wiseek Article
CMND
Apr 15, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Clearmind Medicine Converts $1.75M in Notes at $0.60/Share, Causing Significant Dilution
Sentiment: Negative
View Wiseek Article
CMND
Apr 14, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
9
Clearmind Medicine Secures $1.575M in Highly Dilutive Convertible Note Financing
Sentiment: Negative
View Wiseek Article
CMND
Apr 14, 2026, 8:23 AM EDT
Filing Type: 6-K
Importance Score:
8
Clearmind Medicine's CMND-100 Meets Primary Endpoint in Phase I/IIa AUD Trial
Sentiment: Positive
View Wiseek Article